Background
==========

CAPS is an orphan auto-inflammatory disease, generally diagnosed in childhood that requires life-long treatment. Canakinumab, a fully human anti-IL-1b antibody, has previously demonstrated rapid, complete and sustained response in CAPS patients.

Aim
===

To compare dosing patterns of canakinumab in pediatric and adult CAPS patients of a predominantly Western population (WP) vs Japanese patients (JP).

Methods
=======

Canakinumab s.c. 150 mg (if \>40 kg) or 2 mg/kg (if ≤40 kg) was dosed every 8 weeks. Step-wise up-titrations in dose were allowed in patients who did not achieve/remain in complete response (CR, Figure [1](#F1){ref-type="fig"}).
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Results
=======

Median duration of treatment was 414 (29-687) days in WP and 337 days (59-373 days) in JP. In the WP, CR was achieved in 85/109 (78%) canakinumab-naive patients. 127/141 (90%) evaluable patients remained in CR throughout the study. 47/166 patients in WP and 11/19 patients in the Japanese study were pediatrics. 36.2% vs 81.8% (WP vs JP) of children received up-titrated and/or more frequent doses. Higher median doses were required in pediatric patients in the JP compared with WP to control MWS and NOMID (Table [1](#T1){ref-type="table"}). 13% vs 45% (WP vs JP) of the children received the maximum permitted dose. None of those children showed an unusual type or frequency of adverse events.

###### 

Canakinumab doses by phenotypes

  Phenotype (n=WP/JP)   Wester population                   Japanese population                                                          
  --------------------- ----------------------------------- ------------------------------------------ --------------------------------- ------------------------------------------
                        Adult^1^ Mean/median (mg) (N=136)   Pediatrics^2^ Mean/mdeian (mg/kg) (N=29)   Adult^1^ Mean/median (mg) (N=8)   Pediatrics^2^ Mean/mdeian (mg/kg) (N=11)
                                                                                                                                         
  MWS (103/7)           200/150                             5.5/4.0                                    225/150                           6.0/6.0
  NOMID (32/11)         299/150                             5.8/4.0                                    300/225                           5.5/6.0
  FCAS (30/0)           189/150                             2.7/2.0                                    \-                                \-

Conclusions
===========

Increased doses of canakinumab were equally efficacious in patients of a WP and Japanese population comprising different CAPS phenotypes without evidence of a change in AE profile. These data suggest that children and patients with more severe CAPS phenotypes, irrespective of ethnicity, require differential dosing.
